Molecular Imaging 2017

Limitations of RECIST

 Not all therapies result in initial shrinkage yet are effective e.g. anti-angiogenic therapies, immunotherapies  Side effects of some therapies can hamper response assessment  Not all lesions are best evaluated in portal venous post contrast phase e.g. hepatocellular carcinoma, renal cell carcinoma